Item 8.01 Other Events.
On
Forward-Looking Statements
This Form 8-K contains forward-looking statements that involve substantial risks
and uncertainties. All statements, other than statements of historical facts,
contained in this Form 8-K, including statements regarding the Company's
strategy, future operations, prospects, plans, objectives of management, the
therapeutic potential for the Company's product candidates and preclinical
programs, the potential benefits of cell-selective expression and the expected
timeline for initiating a Phase 1/2 clinical trial of DB-OTO constitute
forward-looking statements within the meaning of The Private Securities
Litigation Reform Act of 1995. The words "anticipate," "believe," "continue,"
"could," "estimate," "expect," "intend," "may," "might," "objective," "ongoing,"
"plan," "predict," "project," "potential," "should," or "would," or the negative
of these terms, or other comparable terminology are intended to identify
forward-looking statements, although not all forward-looking statements contain
these identifying words. The Company may not actually achieve the plans,
intentions or expectations disclosed in these forward-looking statements, and
you should not place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans, intentions and
expectations disclosed in these forward-looking statements as a result of
various important factors, including: uncertainties inherent in the
identification and development of product candidates, including the timing of
and the Company's ability to obtain approval to initiate clinical development of
its program candidates, whether results from preclinical studies will be
predictive of the results of later preclinical studies and clinical trials,
whether the Company's cash resources are sufficient to fund its foreseeable and
unforeseeable operating expenses and capital expenditure requirements,
uncertainties related to the impact of the COVID-19 pandemic on the Company's
business and operations, as well as the risks and uncertainties identified in
the Company's filings with the
--------------------------------------------------------------------------------
© Edgar Online, source